Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Molnupiravir
Bamlanivimab Nigella Sativa
Bromhexine Nitazoxanide
Budesonide Povidone-Iod..
Casirivimab/i.. Probiotics
Colchicine Proxalutamide
Conv. Plasma Quercetin
Curcumin Remdesivir
Favipiravir Sotrovimab
Fluvoxamine Vitamin A
Hydroxychloro.. Vitamin C
Iota-carragee.. Vitamin D
Ivermectin Zinc
Melatonin

Other Adoption
Vitamin D study #11 of 143   Meta Analysis
6/27 Analysis of outcomes based on serum levels
Mendy et al., medRxiv, doi:10.1101/2020.06.25.20137323 (Preprint)
Factors Associated with Hospitalization and Disease Severity in a Racially and Ethnically Diverse Population of COVID-19 Patients
Source   PDF   Share   Tweet
Retrospective 689 patients showing vitamin D deficiency associated with hospitalization and disease severity.
Mendy et al., 6/27/2020, retrospective, USA, North America, preprint, 4 authors.
risk of death, 7.0% lower, RR 0.93, p = 0.89, high D levels 21 of 600 (3.5%), low D levels 5 of 89 (5.6%), odds ratio converted to relative risk.
risk of combined death/ICU, 16.7% lower, RR 0.83, p < 0.001, high D levels 68 of 600 (11.3%), low D levels 23 of 89 (25.8%), odds ratio converted to relative risk.
risk of ICU admission, 55.3% lower, RR 0.45, p = 0.008, high D levels 47 of 600 (7.8%), low D levels 18 of 89 (20.2%), odds ratio converted to relative risk.
risk of hospitalization, 15.1% lower, RR 0.85, p < 0.001, high D levels 171 of 89 (192.1%), low D levels 45 of 89 (50.6%), odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
All 143 studies   Meta Analysis
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Submit